Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin).
OBJECTIVE
A case of choroidal neovascularization (CNV) secondary to Sorsby fundus dystrophy (SFD) treated with systemic bevacizumab (Avastin).


METHODS
A 41-year-old woman presented with CNV secondary to SFD in her better eye. The patient received three initial infusions of bevacizumab at a dose of 5 mg/kg at 2 week intervals and one additional infusion because of CNV recurrence at the 7 month follow-up.


RESULTS
At 16 month follow-up, visual acuity had improved from 20/50 at baseline to 20/25; optical coherence tomography and fluorescein angiography showed no evidence of CNV activity.


CONCLUSIONS
Systemic bevacizumab seems to be a promising treatment option for CNV secondary to SFD.
Prager
Franz
F
Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Michels
Stephan
S
Geitzenauer
Wolfgang
W
Schmidt-Erfurth
Ursula
U
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D005654:Fundus Oculi; D005799:Genes, Dominant; D006801:Humans; D012164:Retinal Diseases / Q000150:complications* / Q000175:diagnosis / Q000235:genetics* / Q000503:physiopathology; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab